Overview of Comments Received on ICH Guideline E8 (R1) on General Considerations for Clinical Studies

On 7 April 2020 the EMA published an overview of comments received from 40 stakeholders on ICH guideline E8(R1).

The ICH guideline 'General considerations for clinical studies' is intended to describe internationally accepted principles and practices in the design and conduct of clinical studies that will facilitate acceptance of data and results by regulatory authorities, provide guidance on the consideration of quality in the design and conduct of clinical studies across the product lifecycle, including the identification during study planning of factors that are critical to the quality of the study, and the management of risks to those factors during study conduct. It provides an overview of the types of clinical studies performed during the product lifecycle, and describe the aspects of those studies that support the determination of which quality factors are critical to ensuring the protection of study subjects, the integrity of the data, the reliability of results, and the ability of the studies to meet their objectives.

Read the pdf 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /